Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,181,632
-
Share change
-
-1,297,250
-
Total reported value
-
$45,121,455
-
Put/Call ratio
-
71%
-
Price per share
-
$1.66
-
Number of holders
-
83
-
Value change
-
-$188,977,629
-
Number of buys
-
58
-
Number of sells
-
43
Institutional Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q2 2024
As of 30 Jun 2024,
Jade Biosciences, Inc. - COM (AVTE) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,181,632 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sofinnova Investments, Inc., TCG Crossover Management, LLC, Atlas Venture Life Science Advisors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD GROUP INC, BlackRock Inc., Artal Group S.A., MILLENNIUM MANAGEMENT LLC, and BAKER BROS. ADVISORS LP.
This page lists
79
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.